Not Signed In - MacuSight Announces FDA Acceptance Of IND For Novel Ophthalmic Drug Candidate
Wed, 09 Aug 2006 06:00 AM EST
... MacuSight, Inc., a developerof innovative therapeutics for the treatment of severe ocular diseases andconditions, today announced that the United States Food and DrugAdministration (FDA) has accepted the company's Investigational New Drug(IND) application for its proprietary formulation of sirolimus (rapamycin). [click link for full article] ...
Related Topics
- Drug Safety
- Polymyxin B, Bacitracin, and Neomycin Ophthalmic Ointment
- Prescription Drugs
- Drug Side Effects
- Drug Abuse
- Trimethoprim and Polymyxin Ophthalmic
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Diclofenac Ophthalmic
- Dexamethasone Ophthalmic
- Gatifloxacin Ophthalmic
- Cyclosporine Ophthalmic
- Tacrolimus ointment
- Tobramycin and Dexamethasone Ophthalmic
- Tysabri
- Hydrocortisone, Neomycin, and Polymyxin Ophthalmic Drops
- Ofloxacin Ophthalmic Drops
- Thalidomide
- Sulfacetamide Ophthalmic
email this page
print this page
bookmark this page
feedback on this page
